GB Sciences, Inc. (GBLX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -1.36 Million USD | 100.0% |
| 2022 | -2631.56 Billion USD | -158805696.35% |
| 2021 | 1.65 Million USD | 134.65% |
| 2020 | -4.78 Million USD | 58.89% |
| 2019 | -11.63 Million USD | 50.81% |
| 2018 | -23.65 Million USD | -2.96% |
| 2017 | -22.97 Million USD | -131.83% |
| 2016 | -9.9 Million USD | -46.35% |
| 2015 | -6.77 Million USD | 12.32% |
| 2014 | -7.72 Million USD | -1077.33% |
| 2013 | -655.95 Thousand USD | -1914.54% |
| 2012 | 36.15 Thousand USD | 344.85% |
| 2011 | -14.76 Thousand USD | 97.48% |
| 2010 | -585.29 Thousand USD | 80.26% |
| 2009 | -2.96 Million USD | -2025.85% |
| 2008 | -139.46 Thousand USD | -47.2% |
| 2007 | -94.74 Thousand USD | 83.01% |
| 2006 | -557.68 Thousand USD | -25.26% |
| 2005 | -445.22 Thousand USD | -18.26% |
| 2004 | -376.48 Thousand USD | -428.59% |
| 2003 | -71.22 Thousand USD | 5.67% |
| 2002 | -75.5 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q1 | -273.12 Thousand USD | 94.69% |
| 2023 Q3 | -187.27 Thousand USD | 56.87% |
| 2023 Q4 | -467.04 Thousand USD | -149.39% |
| 2023 FY | -1.36 Million USD | 100.0% |
| 2023 Q2 | -434.23 Thousand USD | -58.99% |
| 2022 Q3 | -490.24 Thousand USD | -39.96% |
| 2022 Q4 | -5.13 Million USD | -948.37% |
| 2022 FY | -2631.56 Billion USD | -158805696.35% |
| 2022 Q1 | -536.66 Thousand USD | 91.97% |
| 2022 Q2 | -350.27 Thousand USD | 34.73% |
| 2021 Q2 | -555.85 Thousand USD | 12.11% |
| 2021 Q3 | 4.32 Million USD | 878.18% |
| 2021 Q4 | -6.68 Million USD | -254.58% |
| 2021 FY | 1.65 Million USD | 134.65% |
| 2021 Q1 | -632.41 Thousand USD | -32.06% |
| 2020 FY | -4.78 Million USD | 58.89% |
| 2020 Q1 | -1.84 Million USD | 78.6% |
| 2020 Q4 | -478.88 Thousand USD | 19.38% |
| 2020 Q2 | -805.45 Thousand USD | 56.38% |
| 2020 Q3 | -593.98 Thousand USD | 26.26% |
| 2019 Q2 | -2.68 Million USD | -11.48% |
| 2019 FY | -11.63 Million USD | 50.81% |
| 2019 Q1 | -2.4 Million USD | 51.7% |
| 2019 Q3 | 1.34 Million USD | 150.11% |
| 2019 Q4 | -8.62 Million USD | -741.76% |
| 2018 Q4 | -4.98 Million USD | -32.41% |
| 2018 Q1 | -5.16 Million USD | 47.16% |
| 2018 Q3 | -3.76 Million USD | 61.36% |
| 2018 Q2 | -9.73 Million USD | -88.48% |
| 2018 FY | -23.65 Million USD | -2.96% |
| 2017 Q3 | -6.96 Million USD | -121.37% |
| 2017 Q1 | -3.08 Million USD | -19.58% |
| 2017 FY | -22.97 Million USD | -131.83% |
| 2017 Q4 | -9.77 Million USD | -40.46% |
| 2017 Q2 | -3.14 Million USD | -2.04% |
| 2016 FY | -9.9 Million USD | -46.35% |
| 2016 Q4 | -2.57 Million USD | 26.87% |
| 2016 Q2 | -2.46 Million USD | -84.03% |
| 2016 Q1 | -1.34 Million USD | 18.83% |
| 2016 Q3 | -3.52 Million USD | -42.84% |
| 2015 Q2 | -2.68 Million USD | -99.81% |
| 2015 FY | -6.77 Million USD | 12.32% |
| 2015 Q1 | -1.34 Million USD | 66.34% |
| 2015 Q4 | -1.65 Million USD | -50.59% |
| 2015 Q3 | -1.09 Million USD | 59.09% |
| 2014 Q1 | -1.44 Million USD | -105.1% |
| 2014 Q4 | -3.98 Million USD | -541.2% |
| 2014 FY | -7.72 Million USD | -1077.33% |
| 2014 Q3 | -621.62 Thousand USD | 62.78% |
| 2014 Q2 | -1.67 Million USD | -15.56% |
| 2013 Q3 | -183.04 Thousand USD | -166.82% |
| 2013 Q2 | 273.95 Thousand USD | 749.12% |
| 2013 Q1 | -42.2 Thousand USD | 88.19% |
| 2013 FY | -655.95 Thousand USD | -1914.54% |
| 2013 Q4 | -704.65 Thousand USD | -284.96% |
| 2012 Q1 | 334.6 Thousand USD | -29.14% |
| 2012 Q4 | -357.31 Thousand USD | -497.21% |
| 2012 FY | 36.15 Thousand USD | 344.85% |
| 2012 Q2 | -31.09 Thousand USD | -109.29% |
| 2012 Q3 | 89.95 Thousand USD | 389.29% |
| 2011 Q2 | -74.58 Thousand USD | 80.31% |
| 2011 Q3 | -33.55 Thousand USD | 55.01% |
| 2011 Q4 | 472.22 Thousand USD | 1507.43% |
| 2011 FY | -14.76 Thousand USD | 97.48% |
| 2011 Q1 | -378.85 Thousand USD | -4205.88% |
| 2010 Q4 | 9227.00 USD | 108.99% |
| 2010 Q1 | -351.97 Thousand USD | 13.7% |
| 2010 FY | -585.29 Thousand USD | 80.26% |
| 2010 Q3 | -102.59 Thousand USD | 26.7% |
| 2010 Q2 | -139.95 Thousand USD | 60.24% |
| 2009 Q2 | -1.96 Million USD | -6436.68% |
| 2009 Q3 | -557.72 Thousand USD | 71.68% |
| 2009 Q4 | -407.84 Thousand USD | 26.87% |
| 2009 FY | -2.96 Million USD | -2025.85% |
| 2009 Q1 | -30.12 Thousand USD | 23.41% |
| 2008 Q2 | -24.49 Thousand USD | 54.35% |
| 2008 Q3 | -21.99 Thousand USD | 10.21% |
| 2008 FY | -139.46 Thousand USD | -47.2% |
| 2008 Q4 | -39.33 Thousand USD | -78.85% |
| 2008 Q1 | -53.65 Thousand USD | -322.82% |
| 2007 Q3 | -31.18 Thousand USD | -1404.39% |
| 2007 Q4 | 24.07 Thousand USD | 177.2% |
| 2007 Q2 | 2391.00 USD | 102.53% |
| 2007 Q1 | -94.46 Thousand USD | 71.37% |
| 2007 FY | -94.74 Thousand USD | 83.01% |
| 2006 Q4 | -329.97 Thousand USD | -765.96% |
| 2006 Q2 | -30.16 Thousand USD | 81.08% |
| 2006 FY | -557.68 Thousand USD | -25.26% |
| 2006 Q1 | -159.44 Thousand USD | 12.23% |
| 2006 Q3 | -38.1 Thousand USD | -26.34% |
| 2005 Q1 | -84.11 Thousand USD | 9.3% |
| 2005 FY | -445.22 Thousand USD | -18.26% |
| 2005 Q3 | -86.05 Thousand USD | 7.85% |
| 2005 Q2 | -93.39 Thousand USD | -11.03% |
| 2005 Q4 | -181.66 Thousand USD | -111.09% |
| 2004 Q4 | -92.73 Thousand USD | 49.01% |
| 2004 Q3 | -181.86 Thousand USD | -105.03% |
| 2004 Q1 | -13.18 Thousand USD | 44.93% |
| 2004 Q2 | -88.7 Thousand USD | -573.0% |
| 2004 FY | -376.48 Thousand USD | -428.59% |
| 2003 Q3 | -13.68 Thousand USD | -3.13% |
| 2003 FY | -71.22 Thousand USD | 5.67% |
| 2003 Q4 | -23.93 Thousand USD | -74.93% |
| 2003 Q1 | -20.34 Thousand USD | -24.28% |
| 2003 Q2 | -13.26 Thousand USD | 34.78% |
| 2002 Q3 | -29.44 Thousand USD | -113.26% |
| 2002 FY | -75.5 Thousand USD | 0.0% |
| 2002 Q4 | -16.36 Thousand USD | 44.4% |
| 2002 Q1 | -15.89 Thousand USD | 0.0% |
| 2002 Q2 | -13.8 Thousand USD | 13.12% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -1.965% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 80.5% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 102.57% |
| Nascent Biotech, Inc. | -2.08 Million USD | 34.776% |
| Rebus Holdings, Inc. | -1.02 Million USD | -33.498% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 102.091% |
| Qrons Inc. | -789.34 Thousand USD | -72.507% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -115.317% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 97.825% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -227.737% |
| Skye Bioscience, Inc. | -37.64 Million USD | 96.383% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 98.184% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 79.294% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -398.049% |
| SQZ Biotechnologies Company | -79.46 Million USD | 98.286% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 52.922% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 25.204% |
| Mesoblast Limited | -87.95 Million USD | 98.452% |
| Marizyme, Inc. | -65.34 Million USD | 97.916% |
| Genus plc | 7.9 Million USD | 117.236% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 87.498% |
| Pharming Group N.V. | -10.54 Million USD | 87.091% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 37.245% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 63.299% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 84.603% |
| ContraFect Corporation | -65.15 Million USD | 97.91% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 72.131% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 21.174% |
| IMV Inc. | -36.48 Million USD | 96.268% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 83.105% |
| MultiCell Technologies, Inc. | -380.07 USD | -358170.056% |
| ONE Bio Corp. | 8.67 Million USD | 115.694% |
| Accustem Sciences Inc. | -3.74 Million USD | 63.654% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 97.366% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -7.461% |
| Q BioMed Inc. | -2.05 Million USD | 33.644% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 63.523% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 42.808% |
| Biomind Labs Inc. | -1.21 Million USD | -12.135% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 97.72% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 56.1% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 82.77% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 30.144% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -8992.394% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 91.421% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 76.592% |
| Alpha Cognition Inc. | -13.77 Million USD | 90.113% |
| HST Global, Inc. | -146.21 Thousand USD | -831.316% |
| CSL Limited | 2.64 Billion USD | 100.052% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 22.401% |
| Halberd Corporation | -79.67 Thousand USD | -1609.018% |
| Enzolytics Inc. | -2.17 Million USD | 37.447% |
| Agentix Corp. | -1.37 Million USD | 0.912% |
| Resverlogix Corp. | -3.61 Million USD | 62.28% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 57.064% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 99.538% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 1489.466% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 119.664% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 65.727% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 55.003% |
| AVAX Technologies, Inc. | -6.41 Million USD | 78.769% |
| Zenith Capital Corp. | -10.59 Million USD | 87.149% |
| Genscript Biotech Corporation | -95.47 Million USD | 98.574% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -5758.691% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 67.156% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -2152.917% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 32.09% |
| Kadimastem Ltd | -3.3 Million USD | 58.829% |
| Helix BioMedix, Inc. | -1.05 Million USD | -28.94% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 64.345% |
| BioStem Technologies, Inc. | -8.48 Million USD | 83.948% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -208.512% |
| LadRx Corporation | 400.44 Thousand USD | 440.043% |
| Cell Source, Inc. | -5.32 Million USD | 74.41% |
| Regen BioPharma, Inc. | 1.02 Million USD | 233.04% |
| Regen BioPharma, Inc. | 1.02 Million USD | 233.04% |
| NovAccess Global Inc. | -4.76 Million USD | 71.448% |
| Affymax, Inc. | -14.42 Million USD | 90.56% |
| Itoco Inc. | -1.86 Million USD | 27.144% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 69.349% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 18.414% |
| Mobile Lads Corp. | -2.26 Million USD | 39.836% |
| CytoDyn Inc. | -49.84 Million USD | 97.268% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -1622.922% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -496.894% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -44.624% |
| SYBLEU INC | -180.3 Thousand USD | -655.212% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 15.567% |
| International Stem Cell Corporation | -131 Thousand USD | -939.448% |
| Bioxytran, Inc. | -4.28 Million USD | 68.185% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -2408.986% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 46.184% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 97.167% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 35.588% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -74.376% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 57.018% |
| Neutra Corp. | -233.46 Thousand USD | -483.247% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 93.289% |
| PureTech Health plc | -65.69 Million USD | 97.927% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 93.597% |
| IXICO plc | -1.17 Million USD | -15.592% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 86.283% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 97.616% |
| CSL Limited | 2.64 Billion USD | 100.052% |
| Cellectis S.A. | -103.17 Million USD | 98.68% |